Top News
Unplanned Implant Removal Following Treatment for Locally Advanced Breast Cancer
Risk for Cutaneous Squamous Cell Carcinoma Increases With Age
Trodelvy Gets Accelerated Approval for Urothelial Cancer
Prophylactic IVIG Is More Effective in Subgroups of Myeloma
Risk Factors for Pediatric Hemorrhagic Cystitis Following HCT
Tisotumab Vedotin Under Review for Recurrent or Metastatic Cervical Cancer
Daratumumab Not Cost-Effective for Multiple Myeloma
Ixazomib in an Oral Triplet Therapy Shows Benefit for Newly Diagnosed Multiple Myeloma
Genome Sequencing: An Alternative for Risk Stratification in Myeloid Cancers
Umbralisib Has Favorable Benefit-Risk Profile in Pretreated Patients With Indolent Non-Hodgkin Lymphoma
SIRT1 Inhibitor Cambinol Has Antitumor Activity in Multiple Myeloma Cells
EDITORIAL ADVISORY BOARD
E. David Crawford, MD
Jeffrey M. Farma, MD
Featured
-
Recommendations From FDA-AACR Workshop to Increase African American Representation in Multiple Myeloma Clinical Trials
A workshop was convened by the US Food and Drug Administration and the American Association for Cancer Research to create recommendations for trial design and later stages of drug development in multiple myeloma. -
Socioeconomics and Cognitive Function After Childhood Brain Tumors
Researchers hope their findings could lead to targeted interventions to improve cognitive outcomes in pediatric brain tumor survivors from families with low socioeconomic status. -
COVID-19 Vaccination and Imaging Misinterpretation
Oncologists and patients should be aware of the potential manifestations of the COVID-19 vaccination on imaging and the consequences this might have on disease assessment, treatment monitoring, and decision-making. -
Review of Barriers to Colorectal Cancer Screening in Hard-to-Reach Populations
The COVID-19 pandemic sheds new light on existing access challenges in preventive health care. -
Therapeutic Approaches to Multiple Myeloma: An Interview With Ajai Chari, MD
Ajai Chari, MD, of Mount Sinai Hospital in New York City, provides his perspective on the current state of care in multiple myeloma. -
SG-BCC 2021 Coverage
Complete coverage of the 17th St. Gallen International Breast Cancer Symposium. -
NCCN Guidelines for Multiple Myeloma Updated to Include Three Selinexor Regimens
The National Comprehensive Cancer Network’s updated Clinical Practice Guidelines in Oncology for multiple myeloma newly include 3 new selinexor-containing regimens.
More Features
NCCN Releases First Practice Guidelines for Wilms Tumor
New NCCN guidelines for Wilms tumor contain up-to-date information on screening, diagnosis, risk stratification, and treatment for this rare childhood renal cancer.
Pediatric Cancer Survivors and Diabetes: What Are the Risks?
Diabetes and metabolic syndrome represent two of the most common long-term complications in survivors of childhood cancer.
Tepotinib Now Approved to Treat NSCLC With MET Exon 14 Skipping Alterations
Xiuning Le, MD, PhD, discusses the future of tepotinib in the treatment of NSCLC. Dr Le is an author of a phase 2 study on tepotinib, a highly selective MET inhibitor.
Indications Withdrawn as FDA Evaluates Several Accelerated Approvals
To prove clinical benefit, the FDA requires manufacturers to conduct confirmatory trials, also known as a phase 4 studies.
Analysis Shows Disparities in Care Extend to Imaging Studies in Pediatric Patients
An evaluation of a large dataset sought to determine use of imaging studies in children treated in children’s hospital emergency departments.
-
Loading...
-
Loading...
